Kymab

Founded in 2010, Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of novel human antibody-based therapies in a broad range of indications. Our unique platforms generate a vast repertoire of fully-human, species cross-reactive, and affinity-matured antibodies against challenging targets. The company is headquartered in Cambridge, United Kingdom.